Bioatla Inc (BCAB)

$1.6

+0.04

(+2.56%)

Market is closed - opens 7 PM, 20 Jun 2024

Insights on Bioatla Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.2% return, outperforming this stock by 132.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 242.2% return, outperforming this stock by 338.2%

Performance

  • $1.52
    $1.67
    $1.60
    downward going graph

    5.0%

    Downside

    Day's Volatility :8.98%

    Upside

    4.19%

    downward going graph
  • $1.24
    $4.02
    $1.60
    downward going graph

    22.5%

    Downside

    52 Weeks Volatility :69.15%

    Upside

    60.2%

    downward going graph

Returns

PeriodBioatla IncSector (Health Care)Index (Russel 2000)
3 Months
-32.77%
0.3%
0.0%
6 Months
-20.79%
9.9%
0.0%
1 Year
-58.33%
10.9%
0.0%
3 Years
-95.8%
17.9%
-20.9%

Highlights

Market Capitalization
77.0M
Book Value
$1.03
Earnings Per Share (EPS)
-2.48
Wall Street Target Price
9.75
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-53.28%
Return On Equity TTM
-115.68%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
31.6%
Gross Profit TTM
-79.3M
EBITDA
-124.0M
Diluted Eps TTM
-2.48
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.61
EPS Estimate Next Year
-1.48
EPS Estimate Current Quarter
-0.79
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Bioatla Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 509.38%

Current $1.60
Target $9.75

Technicals Summary

Sell

Neutral

Buy

Bioatla Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bioatla Inc
Bioatla Inc
-34.83%
-20.79%
-58.33%
-95.8%
-94.84%
Moderna, Inc.
Moderna, Inc.
-5.49%
54.62%
7.28%
-36.0%
777.93%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.25%
23.44%
33.01%
94.49%
224.24%
Novo Nordisk A/s
Novo Nordisk A/s
5.94%
38.98%
74.18%
240.71%
450.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.8%
16.75%
36.36%
148.95%
156.51%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bioatla Inc
Bioatla Inc
NA
NA
NA
-1.61
-1.16
-0.53
NA
1.03
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.68
30.68
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.23
49.23
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.3
30.3
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bioatla Inc
Bioatla Inc
Buy
$77.0M
-94.84%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.1B
777.93%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.5B
224.24%
30.68
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$629.2B
450.86%
49.23
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.6B
156.51%
30.3
39.46%

Institutional Holdings

  • Soleus Capital Management, L.P.

    8.45%
  • BlackRock Inc

    5.78%
  • Vanguard Group Inc

    4.36%
  • Morgan Stanley - Brokerage Accounts

    3.97%
  • TANG CAPITAL MANAGEMENT LLC

    3.06%
  • Deutsche Bank AG

    2.59%

Company Information

bioatla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. the culmination of our discovery and evolution expertise and more than 150 issued patents and patent applications is our conditionally active biologics (cab) platform, whereby monoclonal antibodies or other biologics can be engineered for selective conditional activation, for example preferential binding under the unique conditions of the tumor microenvironment. this improvement in tumor selectivity helps address the issue of on-target toxicity and improve therapeutic index. bioatla is applying these technologies in our own pipeline and in partnerships to ultimately deliver better immunotherapies for cancer.

Organization
Bioatla Inc
Employees
65
CEO
Dr. Jay M. Short Ph.D.
Industry
Healthcare

FAQs